LAUSR

is further classified as “not otherwise specified” or “with recurrent genetic abnormalities” [1]. The table below shows these classifications, including the subclassifications for B-cell lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities. The L3 category of the FAB classification [2] is part of the Burkitt lymphoma category of mature B-cell neoplasms in the WHO classification, and is not included in the ALL/ LBL category [1]. Prognostic factors are age, initial white blood cell (WBC) count, time to complete remission (CR), and the Philadelphia (Ph) chromosome or t(4;11) [3]. Patients with the Ph chromosome (B lymphoblastic leukemia/lymphoma with t(9;22) (q34;q11.2); BCR–ABL1) have been shown to respond to imatinib and other tyrosine kinase inhibitors (TKIs). For this reason, testing for the Ph chromosome or BCR–ABL1 fusion gene is critical in treatment selection.